Portable medical Dx co attracts $10.8m series B
This article was originally published in Clinica
Cambridge, Massachusetts start-up T2 Biosystems has raised $10.8m in series B financing which it will use to accelerate the development of what it claims to be the "first portable medical diagnostic products that combine nanotechnology and miniaturised magnetic resonance technology". The funds came from new investors Partners Healthcare and In-Q-Tel and from existing shareholders Flagship Ventures, Polaris Venture Partners and Flybridge Capital Partners. T2's devices will allow accurate, immediate patient testing for "almost any health condition, in nearly any setting", said the company. The technology has demonstrated that it can accurately analyse viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.